Peanut Allergy - Pipeline Review, H2 2017

  • ID: 4419034
  • Report
  • 86 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aimmune Therapeutics Inc
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • BioLingus AG
  • HAL Allergy BV
  • Sanofi
  • MORE
Peanut Allergy - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 5, 7 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aimmune Therapeutics Inc
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • BioLingus AG
  • HAL Allergy BV
  • Sanofi
  • MORE
Introduction

Peanut Allergy - Overview

Peanut Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peanut Allergy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peanut Allergy - Companies Involved in Therapeutics Development

Adverum Biotechnologies Inc

Aimmune Therapeutics Inc

Alfacyte Ltd

Allergy Therapeutics Plc

AnaptysBio Inc

ASIT Biotech SA

Astellas Pharma Inc

BioLingus AG

DBV Technologies SA

HAL Allergy BV

Intrommune Therapeutics

Sanofi

Selecta Biosciences Inc

Peanut Allergy - Drug Profiles

aldesleukin - Drug Profile

Allergen for Peanut Allergy - Drug Profile

Allergen for Peanut Allergy - Drug Profile

Allergen for Peanut Allergy - Drug Profile

Allergen for Peanut Allergy - Drug Profile

ANB-020 - Drug Profile

ANN-004 - Drug Profile

AR-101 - Drug Profile

ASP-0892 - Drug Profile

DBV-712 - Drug Profile

Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile

HALMPE-1 - Drug Profile

INT-301 - Drug Profile

PER-1080 - Drug Profile

pnut-ASIT - Drug Profile

Polyvac Peanut - Drug Profile

PVX-108 - Drug Profile

SAR-439794 - Drug Profile

SCV-204 - Drug Profile

Vaccine 2 for Peanut Allergy - Drug Profile

Vaccine for Peanut Allergy - Drug Profile

Vaccine for Peanut Allergy - Drug Profile

VTC-064 - Drug Profile

Peanut Allergy - Dormant Projects

Peanut Allergy - Discontinued Products

Peanut Allergy - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peanut Allergy, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H2

Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H2

Peanut Allergy - Pipeline by Alfacyte Ltd, H2

Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2

Peanut Allergy - Pipeline by AnaptysBio Inc, H2

Peanut Allergy - Pipeline by ASIT Biotech SA, H2

Peanut Allergy - Pipeline by Astellas Pharma Inc, H2

Peanut Allergy - Pipeline by BioLingus AG, H2

Peanut Allergy - Pipeline by DBV Technologies SA, H2

Peanut Allergy - Pipeline by HAL Allergy BV, H2

Peanut Allergy - Pipeline by Intrommune Therapeutics, H2

Peanut Allergy - Pipeline by Sanofi, H2

Peanut Allergy - Pipeline by Selecta Biosciences Inc, H2

Peanut Allergy - Dormant Projects, H2

Peanut Allergy - Discontinued Products, H2

List of Figures

Number of Products under Development for Peanut Allergy, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adverum Biotechnologies Inc
  • Aimmune Therapeutics Inc
  • Alfacyte Ltd
  • Allergy Therapeutics Plc
  • AnaptysBio Inc
  • ASIT Biotech SA
  • Astellas Pharma Inc
  • BioLingus AG
  • DBV Technologies SA
  • HAL Allergy BV
  • Intrommune Therapeutics
  • Sanofi
  • Selecta Biosciences Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll